Medicine and HealthNature Medicine
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial
J. Rodón, S. Damian, et al.
In this fascinating phase 2 study, pemigatinib, an innovative FGFR1-FGFR3 inhibitor, demonstrated a striking effectiveness in patients with advanced solid tumors that have FGFR alterations. Conducted by a team of esteemed researchers including Jordi Rodón and Silvia Damian, this research uncovers not only response rates but also the intricate resistance mechanisms in play. Discover the promising future of FGFR inhibition!
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
MYC targeting by OMO-103 in solid tumors: a phase 1 trial
E. Garralda, M. Beaulieu, et al.
Medicine and Health
Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm study
J. An, X. Li, et al.
Medicine and Health
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial
M. Schuler, K. Cuppens, et al.
Medicine and Health
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
J. F. E. Mann, P. Rossing, et al.
